1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 1, 09/Jan/2025
  4. Article
Editorial Open Access
Like 0
Download
Preview this article:
Preview Magnify

There is no abstract available.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.1.2501091
2025-01-09
2025-01-15
/content/10.2807/1560-7917.ES.2025.30.1.2501091
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/1/eurosurv-30-1-1.html?itemId=/content/10.2807/1560-7917.ES.2025.30.1.2501091&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). WHO Director-General declares mpox outbreak a public health emergency of international concern. Geneva: WHO; 2024. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern
  2. Masirika LM, Udahemuka JC, Schuele L, Ndishimye P, Otani S, Mbiribindi JB, et al. Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the Congo, 2024. Euro Surveill. 2024;29(11):2400106.  https://doi.org/10.2807/1560-7917.ES.2024.29.11.2400106  PMID: 38487886 
  3. Nizigiyimana A, Ndikumwenayo F, Houben S, Manirakiza M, van Lettow M, Liesenborghs L, et al. Epidemiological analysis of confirmed mpox cases, Burundi, 3 July to 9 September 2024. Euro Surveill. 2024;29(42):2400647.  https://doi.org/10.2807/1560-7917.ES.2024.29.42.2400647  PMID: 39421954 
  4. Nzoyikorera N, Nduwimana C, Schuele L, Nieuwenhuijse DF, Koopmans M, Otani S, et al. Monkeypox Clade Ib virus introduction into Burundi: first findings, July to mid-August 2024. Euro Surveill. 2024;29(42):2400666.  https://doi.org/10.2807/1560-7917.ES.2024.29.42.2400666  PMID: 39421956 
  5. Wawina-Bokalanga T, Akil-Bandali P, Kinganda-Lusamaki E, Lokilo E, Jansen D, Amuri-Aziza A, et al. Co-circulation of monkeypox virus subclades Ia and Ib in Kinshasa Province, Democratic Republic of the Congo, July to August 2024. Euro Surveill. 2024;29(38):2400592.  https://doi.org/10.2807/1560-7917.ES.2024.29.38.2400592  PMID: 39301745 
  6. Treutiger C-J, Filén F, Rehn M, Aarum J, Jacks A, Gisslén M, et al. First case of mpox with monkeypox virus clade Ib outside Africa in a returning traveller, Sweden, August 2024: public health measures. Euro Surveill. 2024;29(48):2400740.  https://doi.org/10.2807/1560-7917.ES.2024.29.48.2400740  PMID: 39611206 
  7. de Jong R, Schauer J, Kossow A, Scharkus S, Jurke A. Response of the German public health service to the first imported mpox clade Ib case in Germany, October 2024. Euro Surveill. 2024;29(48):2400743.  https://doi.org/10.2807/1560-7917.ES.2024.29.28.2400743  PMID: 39611210 
  8. Sacco C, Liverani A, Venturi G, Gavaudan S, Riccardo F, Salvoni G, et al. Autochthonous dengue outbreak in Marche Region, Central Italy, August to October 2024. Euro Surveill. 2024;29(47):2400713.  https://doi.org/10.2807/1560-7917.ES.2024.29.47.2400713  PMID: 39574388 
  9. European Medicines Agency (EMA). Beyfortus (nirsevimab) An overview of Beyfortus and why it is authorised in the EU. Amsterdam: EMA; 2022. [Accessed 20 Dec 2023]. Available from: https://www.ema.europa.eu/en/documents/overview/beyfortus-epar-medicine-overview_en.pdf
  10. Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024;29(4):2400033.  https://doi.org/10.2807/1560-7917.ES.2024.29.4.2400033  PMID: 38275017 
  11. López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024;29(6):2400046.  https://doi.org/10.2807/1560-7917.ES.2024.29.6.2400046  PMID: 38333937 
  12. Rendi-Wagner P. Protecting public health in Europe: building trust in a challenging world. Euro Surveill. 2024;29(29):2400461.  https://doi.org/10.2807/1560-7917.ES.2024.29.29.2400461  PMID: 39027942 
  13. Eurosurveillance editorial team. Eurosurveillance reviewers in 2024. Euro Surveill. 2025;30(1):2501097.  https://doi.org/10.2807/1560-7917.ES.2025.30.1.2501097 
  14. Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 2016;1(1):2.  https://doi.org/10.1186/s41073-016-0007-6  PMID: 29451543 
  15. Horn L, Alba S, Gopalakrishna G, Kleinert S, Kombe F, Lavery JV, et al. The Cape Town Statement on Fostering Research Integrity through Fairness and Equity advocates for fair practice from conception to implementation of research and provides 20 recommendations aimed at all involved stakeholders. 7th World Conference on Research Integrity (7th WCRI); 29 May–1 June 2022, Cape Town, South Africa. Available from: https://www.wcrif.org/guidance/cape-town-statement
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error